Edesa Biotech, Inc. (EDSA): who owns it and who trades it
As of Nov 16, 2026, EDSA insiders reported 9 purchases worth $233K in the last 12 months. The largest buyer was Pardeep Nijhawan (CEO), with $230K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Edesa Biotech
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns EDSA
32 funds and institutions reported EDSA shares worth $30M at the end of Q2 2026, about 42% of the company. The largest holder is Velan Capital Investment Management LP with 9.3%.
Funds and institutions (13F) 42%Everyone else 58%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 827,500 | 9.31% | $6.7M | No change |
| Rubric Capital Management LP | 669,500 | 7.53% | $5.4M | -3% |
| Perceptive Advisors LLC | 563,239 | 6.33% | $4.6M | No change |
| Millennium Management LLC | 561,751 | 6.32% | $4.6M | New |
| Stonepine Capital Management, LLC | 456,439 | 5.13% | $3.2M | +1421% |
| Boxer Capital Management, LLC | 205,000 | 2.31% | $1.7M | New |
| Vanguard Capital Management LLC | 81,839 | 0.92% | $665K | -5% |
| Geode Capital Management, LLC | 80,879 | 0.91% | $658K | +5% |
| Jane Street Group, LLC | 72,465 | 0.81% | $589K | -37% |
| Vanguard Fiduciary Trust Co | 38,718 | 0.44% | $315K | +1% |
| State Street Corp | 37,979 | 0.43% | $309K | No change |
| XTX Topco Ltd | 35,352 | 0.40% | $287K | New |
| Hrt Financial LP | 31,531 | 0.35% | $256K | New |
| BlackRock, Inc. | 27,495 | 0.31% | $224K | -1% |
| Northern Trust Corp | 14,994 | 0.17% | $122K | No change |
| Scotia Capital Inc. | 14,393 | 0.16% | $117K | -9% |
| Two Sigma Investments, LP | 14,032 | 0.16% | $114K | New |
| UBS Group AG | 6,763 | 0.08% | $55K | +189% |
| SBI Securities Co., Ltd. | 3,505 | 0.04% | $28.5K | +0% |
| Federation des caisses Desjardins du Quebec | 2,595 | 0.03% | $21.1K | New |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, EDSA insiders reported $233K of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Mar 10, 2026 | Pardeep Nijhawan | CEO | Purchase | 1,000 | $6.60 | $6.6K | Form 4 |
| Mar 5, 2026 | Pardeep Nijhawan | CEO | Purchase | 10,000 | $3.90 | $39K | Form 4 |
| Mar 4, 2026 | Pardeep Nijhawan | CEO | Purchase | 10,000 | $4.26 | $42.6K | Form 4 |
| Mar 3, 2026 | Pardeep Nijhawan | CEO | Purchase | 10,000 | $3.63 | $36.3K | Form 4 |
| Mar 2, 2026 | Pardeep Nijhawan | CEO | Purchase | 1,000 | $2.28 | $2.3K | Form 4 |
| Mar 2, 2026 | Pardeep Nijhawan | CEO | Purchase | 2,000 | $2.00 | $4K | Form 4 |
| Feb 27, 2026 | Pardeep Nijhawan | CEO | Purchase | 30,000 | $2.22 | $66.6K | Form 4 |
| Feb 26, 2026 | Michael J Brooks | President | Purchase | 2,000 | $1.57 | $3.1K | Form 4 |
| Feb 26, 2026 | Pardeep Nijhawan | CEO | Purchase | 20,571 | $1.58 | $32.5K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Pardeep Nijhawan | Chief Executive Officer, Director, 10% owner | $230K | – | Mar 10, 2026 |
| Michael J Brooks | President | $3.1K | – | Feb 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
EDSA short interest
Low short interest. 1.6% of EDSA shares are sold short: about 1 share in 61. Over the last 12 reports the number of shares short went down 28%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 158,091 EDSA shares were sold short, 1.6% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 39,334 shares, buying them all back would take about 4.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 158,091 | 1.64% | -2% | 39,334 | 4.0 |
| Oct 15, 2026 | 161,309 | 1.67% | -21% | 46,022 | 3.5 |
| Sep 30, 2026 | 203,556 | 2.11% | -7% | 42,306 | 4.8 |
| Sep 15, 2026 | 218,773 | 2.27% | -11% | 32,819 | 6.7 |
| Aug 31, 2026 | 245,430 | 2.55% | +17% | 136,840 | 1.8 |
| Aug 14, 2026 | 208,955 | 2.17% | -3% | 35,741 | 5.8 |
| Jul 31, 2026 | 216,390 | 2.43% | -24% | 73,162 | 3.0 |
| Jul 15, 2026 | 282,929 | 3.18% | -0% | 52,762 | 5.4 |
| Jun 30, 2026 | 283,230 | 3.19% | -1% | 149,603 | 1.9 |
| Jun 15, 2026 | 287,082 | 3.23% | +20% | 294,726 | 1.0 |
| May 29, 2026 | 238,707 | 2.68% | +9% | 419,168 | 1.0 |
| May 15, 2026 | 218,598 | 2.46% | -57% | 363,030 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Edesa Biotech company events
Edesa Biotech filed 14 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AgreementEdesa Biotech, Inc., together with its wholly owned subsidiaries, entered into a Collaboration and License Agreement with Kyorin Pharmaceutical Co., Ltd. Filing
- Oct 23, 2026LeadershipThe Board of Directors of Edesa Biotech, Inc., upon the recommendation of the Compensation Committee of the Board, approved increases in the annual base salaries of Dr. Pardeep Nijhawan, the Company’s Chief Executive Officer, from $357,696 to $657,423, Dr. Michael Brooks, the Company’s President… Filing
- Oct 15, 2026AnnouncementEdesa Biotech, Inc. reported that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug application for its Phase 2 clinical study of EB06 in vitiligo, enabling the Company to expand recruitment to the United States. Filing
- Aug 20, 2026AgreementEdesa Biotech, Inc. entered into an underwriting agreement with Guggenheim Securities, LLC, as representative of the several underwriters listed in Schedule 1 thereto, in connection with the issuance and sale, in an underwritten, registered offering, of: (i) 3,870,500 shares of the Company’s common… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jun 11, 2026AgreementEdesa Biotech, Inc. entered into a Securities Purchase Agreement for a private placement with certain investors (each, a “Purchaser” and collectively, the “Purchasers”). Filing
- Jun 5, 2026AnnouncementEdesa Biotech, Inc. reported favorable exploratory data for paridiprubart, its first-in-class anti-TLR4 monoclonal antibody, in patients with acute kidney injury and respiratory distress. Filing
- May 29, 2026LeadershipEdesa Biotech, Inc. held its 2026 Annual General and Special Meeting of Shareholders. Filing
- May 15, 2026LeadershipThe Board of Directors of Edesa Biotech, Inc., at the request of Pardeep Nijhawan, the Company’s Chief Executive Officer, approved, pursuant to the terms of the Amended and Restated Employment Agreement, dated August 4, 2023, as amended between the Company and Dr. Nijhawan, that 90% of Dr.… Filing
- May 14, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementEdesa Biotech, Inc. announced positive additional data from a Phase 3 study of paridiprubart. Filing
- Feb 13, 2026ResultsReleased financial results. Filing
- Dec 12, 2025AnnouncementEdesa Biotech, Inc., filed a prospectus supplement with the U.S. Securities and Exchange Commission to increase the maximum aggregate offering amount of the Company’s common shares, without par value, issuable under the At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated October… Filing
- Dec 12, 2025ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Edesa Biotech financials
Famous investors that hold EDSA
2 of the 50 well-known investors we track reported holding EDSA in their latest 13F filing. The largest position is Israel Englander's, worth $5M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 1.18M | $5M | 0.0% | +110% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 51,551 | $217K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 14 filings named EDSA in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Boxer Capital Management, LLC | 13G | 6.9% |
| Nov 16, 2026 | StemPoint Capital LP | 13G | 9.9% |
| Nov 16, 2026 | Boxer Capital Management, LLC | 13G | 6.9% |
| Nov 16, 2026 | StemPoint Capital LP | 13G | 9.9% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 9.9% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 4.6% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 4.2% |
| Nov 16, 2026 | Perceptive Advisors LLC | 13G/A | 4.2% |
| Nov 16, 2026 | Rubric Capital Management LP | 13G/A | 4.6% |
| Nov 16, 2026 | Sirenia Capital Management LP | 13G/A | 9.9% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 7.8% |
| Nov 12, 2026 | Adage Capital Management, L.P. | 13G | 7.8% |
| Nov 4, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 8.7% |
| Nov 4, 2026 | Integrated Core Strategies (US) LLC | 13G/A | 8.7% |
Questions about Edesa Biotech, Inc. (EDSA) stock
Who owns the most EDSA stock?
The largest reported owner of Edesa Biotech, Inc. (EDSA) is Velan Capital Investment Management LP, with 9.3% of the company. In total, 32 funds and institutions reported holding EDSA at the end of Q2 2026, together about 42% of the shares. See the largest owners.
Are EDSA insiders buying or selling?
In the last 12 months, EDSA insiders reported 9 open-market purchases worth $233K and no sales. The latest trade was on Mar 10, 2026. See every trade.
What is the short interest in EDSA?
As of Oct 30, 2026, 158,091 EDSA shares were sold short, 1.6% of the shares outstanding, down 2.0% from the report before. At the average daily volume of 39,334 shares, buying them all back would take about 4.0 trading days (days to cover). See the history.
Which famous investors hold EDSA?
2 of the 50 well-known investors we track reported EDSA in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.